ClinicalTrials.gg
RecruitingNCT07124351Updated Nov 2, 2026

Intraoperative Imaging of Gastrointestinal Malignancies Using Pafolacianine (CYTALUX™)

A Phase 4 interventional study of CYTALUX™ (pafolacianine) in Gastrointestinal Cancer, Gastric Cancer and Esophageal Cancer, sponsored by Cedars-Sinai Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Cedars-Sinai Medical Center · Phase 4, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.
Updated Nov 2, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 316 studies in Gastrointestinal Neoplasms with a site in United States — 83 open to participants now, 116 under way, 4 of them phase 3. Gastrointestinal Neoplasms · United States.

Planned enrollment
212th of 245
15 · median 60
Started
2025
with 20 others
Phase 4
4 of 316
1 open now
Primary completion
2027-08
later than 56 of 113 live
Registered
294th of 316
by date

Among the 316 studies in Gastrointestinal Neoplasms with a site in United States, this one is the 212th largest by planned enrollment of the 245 interventional ones that give a count, is one of 21 that started in 2025, is one of 4 in phase 4, reaches primary completion later than 56 of the 113 other live ones, and was the 294th registered.

Gastrointestinal Neoplasms

698 studies on the registry are indexed under Gastrointestinal Neoplasms; 211 are open to participants now.

Browse Gastrointestinal Neoplasms studies →

Open to participants now

83 of the 316 studies in Gastrointestinal Neoplasms with a site in United States are open now. Recruiting first, the newest first:

77 more — sign in →

All 83 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 160 Gastrointestinal Neoplasms studies recruiting now, 121 (76%) set no upper age limit and 19 (12%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 316 studies in Gastrointestinal Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This is an open-label study in adults to determine feasibility of using CYTALUX™ (pafolacianine) injection with near-infrared (NIR) fluorescent imaging for detecting any type adenocarcinoma (gastric, esophageal and appendiceal).

03

Conditions studied

  • Gastrointestinal Cancer
  • Gastric Cancer
  • Esophageal Cancer
  • Appendiceal Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients 18 years of age and older of any sex.
  2. Have a primary diagnosis, or a high clinical suspicion, of gastroesophageal adenocarcinoma based on CT (computed tomography)/PET (positron emission tomography) or other imaging (Cohort 1) or diagnosis of appendiceal adenocarcinoma with a high clinical suspicion of peritoneal carcinomatosis (Cohort 2).
  3. Have an indication for surgical intervention for gastroesophageal tumor resection or diagnostic laparoscopy for assessment of peritoneal disease burden.
  4. Willingness to stop the use of folate, folic acid, or folate-containing supplements within 48 hours before administration of CYTALUX.
  5. Willingness of research participant to give written .

Exclusion criteria

Exclusion Criteria:

  1. Any medical condition that in the opinion of the investigators could potentially jeopardize the safety of the subject.
  2. History of anaphylactic reactions to products containing indocyanine green for near infrared imaging. Subjects with a medical history of 'idiopathic anaphylaxis' will require evaluation.
  3. History of allergy to any of the components of CYTALUX™ (pafolacianine) injection.
  4. Presence of any psychological, familial, sociological condition or geographical challenges potentially hampering compliance with the study protocol or follow-up schedule.
  5. Known sensitivity to fluorescent light.
  6. Women of who are pregnant or plan to become pregnant during the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 4
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    CYTALUX™ (pafolacianine)

    Enrolled subjects will be dosed with 0.025 mg/kg CYTALUX™ (pafolacianine) injection intravenously, with the hour-long infusion completing from 1 hour to up to 24 hours prior to imaging for the planned surgery.

    Drug: CYTALUX™ (pafolacianine)

Interventions

  • DrugPafolacianineStudies of PafolacianinePafolacianine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    All subjects participating in the study are expected to receive CYTALUX™ (pafolacianine) injection and standard care surgery; 1 to 24 hours after CYTALUX™ (pafolacianine) injection infusion is completed, all tumors planned to be removed as part of standard care will undergo assessment with NIR light imaging both intraoperatively and on the back table following surgery.

06

What researchers measure

Primary outcomes

  1. Feasibility of CYTALUX™ (pafolacianine) with near-infrared (NIR) fluorescent imaging

    Determine feasibility of using CYTALUX™ (pafolacianine) injection with near-infrared (NIR) fluorescent imaging for detecting any type adenocarcinoma (gastric, esophageal and appendiceal) in at least 70% of the patients.

    Time frame: 12 months

Secondary outcomes

  1. Number of Lesions

    Number of lesions that are simultaneously fluorescence positive and cancer positive.

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Sep 2025 (actual). Primary completion is estimated for Aug 2027, 23 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: primary completion Aug 2026 → Aug 2027 and completion Sep 2026 → Sep 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2025
First posted
Aug 15, 2025
StartActual
Sep 5, 2025
Primary completionEst.
Aug 31, 2027was Aug 2026
CompletionEst.
Sep 30, 2027was Sep 2026
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 2026→Aug 31, 2027
Nov 2, 2026
Study completion
Sep 2026→Sep 30, 2027
Nov 2, 2026
Contact
Study contact changed: a•••@cshs.org · •••1542→A•••@cshs.org · •••6716. See the current contact
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Primary completion Aug 2026→Aug 31, 2027
    Study completion Sep 2026→Sep 30, 2027
    Contact Study contact changed: a•••@cshs.org · •••1542→A•••@cshs.org · •••6716. See the current contact
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07124351
Collaborators
On Target Laboratories, LLC
Responsible party
Miguel Burch (Principal Investigator, Cedars-Sinai Medical Center) — Principal investigator
First posted
Aug 15, 2025
Start date
Sep 5, 2025
Primary completion
Aug 31, 2027 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Nov 2, 2026

Study contacts

Laura Sarmiento
Contact
Laura.sarmiento@cshs.org
310-423-4295
Arman Jordan
Contact
Arman.Jordan@cshs.org
310-248-6716
Miguel Burch, MD
principal investigator · Cedars-Sinai Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pafolacianine

Start the discussion